SECONDARY PULMONARY HYPERTENSION: SOME ASPECTS OF PATHOGENESIS


Cite item

Full Text

Abstract

Aim. To study morphofunctional condition of pulmonary vessels in chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), to specify the role of endothelial dysfunction in pathogenesis of secondary pulmonary hypertension (SPH). Material and methods. Functional examination of cardiovascular and respiratory systems, measurement of systolic pressure (SP) in the pulmonary artery were made in 178 patients: 99 with COPD (8 females and 91 males, mean age 57.2 ± 9.8 years), 79 with IPF (58 females and 21 males, mean age 54.1 ± 12.7 years). The examination has detected echocardiographic signs of pulmonary hypertension (PH). Then 45 PH patients (22 with COPD and 23 with IPF) were tested for vasoreactivity in response to inhalation of O 2, NO in combination with O 2 and iloprost (prostacycline i 2) with О 2. Next stage of the study was morphometric and immunohistochemical examinations of small branches of the pulmonary artery (PA). Results. PA SP in COPD patients was 42.8 ± 11.1 mmHg, in IPF patients — 41.8 ± 12.6 mmHg. Elevation of PA SP above 35 mmHg was registered in 48.5% patients with COPD and in 43.0% with IPF. Patients of both groups responded to a vasodilating impact of inhalatory NO and iloprost while reaction to O 2 inhalation was absent. Morphological study of PA small branches revealed marked changes in the structure of vascular wall which were most manifest in the intima. Conclusion. The findings evidence for an essential role of endothelial dysfunction in formation and progression of PH in pulmonary pathology.

About the authors

G V Neklyudova

Research Institute of Pulmonology

Email: Nekludova-gala@mail.ru
д-р мед. наук, ст. науч. сотр. лаб. функциональных и ультразвуковых методов исследования

S N Avdeev

Research Institute of Pulmonology

д-р мед. наук, проф., зам. дир

N A Tsareva

Research Institute of Pulmonology

канд. мед. наук, зав. лаб. интенсивной терапии и дыхательной недостаточности

A L Chernyaev

Research Institute of Pulmonology

д-р мед. наук, проф., зав. отд. патологии

M V Samsonova

Research Institute of Pulmonology

д-р мед. наук, зав. лаб. патологической анатомии и иммунологии

Zh K Naumenko

Research Institute of Pulmonology

канд. мед. наук, ст. науч. сотр. лаб. функциональных и ультразвуковых методов исследования

L M Mikhale

Research Institute of Human Morphology

д-р мед. наук, проф., акад. РАЕН, зав. лаб. клинической морфологии УРАМН НИИ морфологии человека РАМН

References

  1. Weitzenblum E., Hirth C., Ducolone A. et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36: 752—758.
  2. Kessler R., Faller M., Fourgaut G. et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159 (1): 158—164.
  3. Nathan S. D., Noble P. W., Tuder R. M. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am. J. Respir. Crit. Care Med. 2007; 175 (9): 875—880.
  4. Rubin L. J. Primary pulmonary hypertension. Chest 1993; 104 (1): 236—250.
  5. Замотаев И. П. Легочно-сердечная недостаточность. М.: Медицина; 1978: 200.
  6. Weitzenblum E., Sautegeau A., Ehrrhart M. et al. Long-term course of pulmonary arterial pressure in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1984; 130: 993—998.
  7. Ландышева И. В. Хроническое легочное сердце. Благовещенск; 1980: 173.
  8. Nakamura A., Kasamatsu N., Hashizume I. et al. Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. Respiration 2000; 67: 502—506.
  9. Dinh-Xuan A. T., Higgenbottam T. W., Clelland C. A. et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N. Engl. J. Med. 1991; 324: 1539—1547.
  10. Galie N., Rubin L. J. et al. Pulmonary Arterial Hypertension: epidemiology, pathobiology, assessment, and therapy. J. Am. Coll. Cardiol. 2004; 12: 5S—12S.
  11. Ignarro L. J. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 1989; 65: 1—21.
  12. Global Strategy for Diagnosis, Management, and Prevention of COPD (updated 2009). www.goldcopd.org.
  13. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement — American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000; 161: 646—664.
  14. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165: 277—304.
  15. Hart C. M. Nitric oxide in adult lung disease. Chest 1999; 115: 1407—1417.
  16. Yoshida M., Taguchi O., Gabazza E. C. et al. The effect of low-dose inchalation of nitric oxide in patients with pulmonary fibrosis. Eur. Respir. J. 1997; 10: 2051—2054.
  17. Quanjer Ph. H., Tammeling G., Cotes J. E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6 (suppl. 16): 5—40.
  18. Berger M., Haimovitz A., Van Tosh A. et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J. Am. Coll. Cardiol. 1985; 6: 359—365.
  19. Kircher B., Himelman R. B., Schiller M. B. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am. J. Cardiol. 1990; 15; 66 (4): 493—496.
  20. Автандилов Г. Г. Морфометрия в патологии. М.: Медицина; 1973: 248.
  21. Germann P., Braschi A., Della Rocca G. et al. Inhaled nitric oxide therapy in adults: European expert recommendations. Intensive Care Med. 2005; 31: 1029--1041.
  22. Siobal M. Aerosolized Prostacyclins. Respir. Care. 2004; 49: 640—652.
  23. Snider G. L., Fairley H. B., Palmer J. D., Weg J. C. Scientific basis of oxygen therapy. Chest 1984; 86: 236—239.
  24. O’Driscoll B. R., Howard L. S., Davison A. G. British Thoracic Society. BTS guideline for emergency oxygen use in adult patients. Thorax 2008; 63 (Suppl. VI): vi1--vi68.
  25. Galie’ N., Hoeper M. M., Humbert M. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2009; 30: 2493—2537.
  26. Von Euler U., Lijestrand G. Observations on the pulmonary arterial blood pressure in cat. Acta Physiol. Scand. 1946; 12: 301—320.
  27. Scharf S. M., Iqbal M., Keller C. et al. Hemodynamic characterization of patients with severe emphysema. Am. J. Respir. Crit. Care Med. 2002; 166: 314—322.
  28. Doi M., Nakano K., Hiramoto T., Kohno N. Significance of pulmonary artery pressure in emphysema patienys with mild-to-moderate hypoxemia. Respir. Med. 2003; 97 (8): 915—920.
  29. Naeije R., MacNee W. Pulmonary circulation. In: Calverley P., MacNee W., Pride P., Rennard S., eds. Chronic obstructive pulmonary disease, 2nd ed. London: Arnold Health Sciences; 2003: 228—242.
  30. Nathan S., Shlobin O., Ahmad S. et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657—663.
  31. Hamada K., Nagai S., Tanaka S. et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131 (3): 650—656.
  32. Welte M., Zwissler B., Habazettl H., Messmer K. PGI2 aerosol versus nitic oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur. Surg. Res. 1993; 25: 329—340.
  33. Kouyoumdjian C., Adnot S., Levame M. et al. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats. J. Clin. Invest. 1994; 94: 578—584.
  34. Badesch D. B., Abman S. H., Ahearn G. S. et al. American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (1, Suppl): 35S—62S.
  35. Le Cras T. D., McMurtry I. F Nitric oxide production in the hypoxic lung. Am. J. Physiol. Lung Cell Mol. Physiol. 2001; 280 (4): L575— L582.
  36. Carratu P., Scoditti C., Maniscalco M. et al. Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension. BMC Pulm. Med. 2008; 8: 20.
  37. Trakada G., Nikolaou E., Pouli A. et al. Endothelin-1 levels in interstitial lung disease patients during sleep. Sleep Breath 2003; 7 (3): 111—118.
  38. Shen Q., Chen P., Yang M. et al. The expression of prostacyclin in lung from patients with chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi 2010; 33 (2): 114—117.
  39. Santos S., Peinado V. I., Ramirez J. et al. Characterization of pulmonary vascular remodelling in smokers and patients whith mild COPD. Eur. Respir. J. 2002; 19: 632—638.
  40. Barbera J. A., Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs 2009; 69 (9): 1153—1171.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies